Welcome to the 3rd Annual RNAi – Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics

Built with biopharmaceutical industry insights, this in person conference will bring together key opinion leaders to delve deep into the key remaining challenges associated with targeted delivery, translation, CMC and clinical development of targeted siRNA therapeutics for modular, reproducible and effective gene silencing therapies against oncology, CNS, rare diseases and beyond.

With 30+ pioneering speakers from large pharma, innovative biotech and KOLs of academia who are ready to discuss the full and comprehensive range of RNAi drugs from discovery to development and beyond, join us in Boston to hear how they address the major challenges facing the industry. Register your Interest for 2023.

Key Benefits of Attending

  • Benchmark Against the Latest Strategies to Target Extrahepatic Tissues
    Delve into the latest advancements in applications of siRNA delivery to extrahepatic tissues with case studies into the CNS, skeletal muscle, oncology & more from Lemonex, Aruna Bio, Sirnaomics & TransCode Therapeutics
  • Develop Next Generation of RNAi Drugs with Better Stability & Efficacy
    Explore latest progress in siRNA chemistry to increase activity, stability, specificity & potential off target effects to improve cellular targeting with insights from Silence Therapeutics & Aro Biotherapeutics
  • Debate How to Optimize Effective siRNA Delivery Strategies
    Realize the full potential of RNAi carriers 2.0 beyond GalNac to enhance the performance & biodistribution of your RNAi drugs to ensure you are on the path for success with expert insights from Janssen, Vrata Therapeutics & Sixfold Bioscience
  • Unlock the Mechanistic Functions of siRNAs to Increase Therapeutic Potential
    Leverage the understanding of the endogenous intracellular mechanisms of siRNAs & the strategies to overcome the challenges of endosomal escape for enhanced siRNA therapeutic efficacy with insights from the University of Connecticut & Sapreme Technologies BV
  • Effective Strategies to Advance Analytical Development & CMC of siRNA Therapeutics
    As the industry continues to expand RNAi drug development, it is becoming more important than ever to overcome the hurdles of analytics, raw material supply, & manufacturing. Hear expert insights from AstraZeneca & Abbvie

Expert Speaker Faculty Includes

Julia Alterman

Assistant Professor

RNA Therapeutics Institute, University of Massachusetts Chan Medical School

Uli Stilz

VP

Novo Nordisk Bio Innovation Hub

Marie Wikström Lindholm

SVP & Head of Molecular Design

Silence Therapeutics

David Evans

CSO

Sirnaomics

Tamar Grossman

Global Head of RNA & Targeted Therapeutics

The Janssen Pharmaceutical Companies of Johnson & Johnson

Who Will You Meet?

Copy of companies attending

Health & Safety 

The health, safety and well-being of our community remains our highest priority, therefore, all attendees will be required to complete a health declaration prior to attending the event, as well as comply with the City of Boston’s B Together policy. This policy requires individuals to show you proof of vaccination against COVID-19 in order to gain admittance to the conference venue. For further information around Health and Safety onsite, please visit our FAQs page here or for more information on the B Together Policy, please see here.

*Please note, this is subject to change at any time without prior notice.

Other Events in the Hanson Wade RNA Series